Reversal for heparins and new anticoagulant treatments;Antagonisation des héparines et des nouveaux anticoagulants

Annales Francaises d'Anesthesie et de Reanimation

Volumn 32, Issue 1, 2013, Pages 37-49

  Kortchinsky, T ^a   Vigue B ^b   Samama, C M ^c  

^a CENTRE CHIRURGICAL MARIE LANNELONGUE   (France)

^b BICÊTRE HOSPITAL   (France)

^c HÔTEL DIEU   (France)

Author keywords

Apixaban; Bleeding; Dabigatran; Heparin; Low molecular weight heparins; Pentasaccharides; Protamine; Reversal; Rivaroxaban

Indexed keywords

ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10A INHIBITOR; FONDAPARINUX; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; RECOMBINANT BLOOD CLOTTING FACTOR 7A;

ANTICOAGULANT THERAPY; BLEEDING DISORDER; DISEASE COURSE; DRUG EFFECT; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; EMERGENCY CARE; HUMAN; SHORT SURVEY; THROMBIN TIME;

ANTICOAGULANTS; ANTITHROMBINS; FACTOR XA; HEMORRHAGE; HEPARIN; HEPARIN ANTAGONISTS; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS;

EID: 84872673538     PISSN: 07507658     EISSN: 17696623     Source Type: Journal    
DOI: 10.1016/j.annfar.2012.10.034     Document Type: Short Survey

References (76)

1. Hirsh J., Guyatt G., Albers G.W., Harrington R., Schunemann H.J. Antithrombotic and thrombolytic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008, 133(6 Suppl.):110S-112S.
2. Vigué B. Bench-to-bedside review: optimising emergency reversal of vitamin K antagonists in severe haemorrhage - from theory to practice. Crit Care 2009, 13:209.
3. Levi M. Emergency reversal of antithrombotic treatment. Intern Emerg Med 2009, 4:137-145.
4. Jobin F. La thrombose 1995, Paris, Maloine, p. 209-10.
5. Weitz J.I. Low-molecular-weight heparins. N Engl J Med 1997, 337:688-698.
6. Ubrich N.H.V., Vigneron C., Hoffman C., Maincent P. STP. Pharma Sciences 2002, 12:147-155.
7. Crowther M.A., Warkentin T.E. Bleeding risk and the management of bleeding complications in patients undergoing anticoagulant therapy: focus on new anticoagulant agents. Blood 2008, 111:4871-4879.
8. Freedman K.B., Brookenthal K.R., Fitzgerald R.H., Williams S., Lonner J.H. A meta-analysis of thromboembolic prophylaxis following elective total hip arthroplasty. J Bone Joint Surg Am 2000, 82-A(7):929-938.
9. Mismetti P., Quenet S., Levine M., Merli G., Decousus H., Derobert E., et al. Enoxaparin in the treatment of deep vein thrombosis with or without pulmonary embolism: an individual patient data meta-analysis. Chest 2005, 128:2203-2210.
10. Peterson J.L., Mahaffey K.W., Hasselblad V., Antman E.M., Cohen M., Goodman S.G., et al. Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-Segment elevation acute coronary syndromes: a systematic overview. JAMA 2004, 292:89-96.
11. Turpie A.G., Bauer K.A., Eriksson B.I., Lassen M.R. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. Arch Intern Med 2002, 162:1833-1840.
12. Hull R.D., Pineo G.F., Francis C., Bergqvist D., Fellenius C., Soderberg K., et al. Low-molecular-weight heparin prophylaxis using dalteparin in close proximity to surgery vs warfarin in hip arthroplasty patients: a double-blind, randomized comparison. The North American Fragmin Trial Investigators. Arch Intern Med 2000, 160:2199-2207.
13. [No authors]. Long-term low-molecular-mass heparin in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. FRagmin and Fast Revascularisation during InStability in Coronary artery disease. Investigators. Lancet 1999;354:701-7 [Erratum in Lancet 1999;254:1478].
14. Simonneau G., Sors H., Charbonnier B., Page Y., Laaban J.P., Azarian R., et al. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. The THESEE Study Group. Tinzaparine ou Heparine Standard: évaluations dans l'embolie pulmonaire. N Engl J Med 1997, 337:663-669.
15. Buller H.R., Davidson B.L., Decousus H., Gallus A., Gent M., Piovella F., et al. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann Intern Med 2004, 140:867-873.
16. Yusuf S., Mehta S.R., Chrolavicius S., Afzal R., Pogue J., Granger C.B., et al. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med 2006, 354:1464-1476.
17. Eriksson B.I., Borris L.C., Friedman R.J., Haas S., Huisman M.V., Kakkar A.K., et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008, 358:2765-2775.
18. Kakkar A.K., Brenner B., Dahl O.E., Eriksson B.I., Mouret P., Muntz J., et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 2008, 372:31-39.
19. Lassen M.R., Ageno W., Borris L.C., Lieberman J.R., Rosencher N., Bandel T.J., et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008, 358:2776-2786.
20. Turpie A.G., Lassen M.R., Davidson B.L., Bauer K.A., Gent M., Kwong L.M., et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet 2009, 373:1673-1680.
21. Greinacher A., Eichler P., Lubenow N., Kwasny H., Luz M. Heparin-induced thrombocytopenia with thromboembolic complications: meta-analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range. Blood 2000, 96:846-851.
22. Lewis B.E., Wallis D.E., Leya F., Hursting M.J., Kelton J.G. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia. Arch Intern Med 2003, 163:1849-1856.
23. Ebrahimi R., Lincoff A.M., Bittl J.A., Chew D., Wolski K., Wadhan N., et al. Bivalirudin vs heparin in percutaneous coronary intervention: a pooled analysis. J Cardiovasc Pharmacol Ther 2005, 10:209-216.
24. Eriksson B.I., Dahl O.E., Rosencher N., Kurth A.A., van Dijk C.N., Frostick S.P., et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 2007, 370:949-956.
25. Eriksson B.I., Dahl O.E., Rosencher N., Kurth A.A., van Dijk C.N., Frostick S.P., et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost 2007, 5:2178-52185.
26. Eriksson B.I., Dahl O.E., Huo M.H., Kurth A.A., Hantel S., Hermansson K., et al. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*). A randomised, double-blind, non-inferiority trial. Thromb Haemost 2011, 105:721-729.
27. Eikelboom J.W., Wallentin L., Connolly S.J., Ezekowitz M., Healey J.S., Oldgren J., et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation 2011, 123:2363-2372.
28. Warkentin T.E., Crowther M.A. Reversing anticoagulants both old and new. Can J Anaesth 2002, 49:S11-S25.
29. Caplan S.N., Berkman E.M. Letter: protamine sulfate and fish allergy. N Engl J Med 1976, 295:172.
30. Lindblad B., Borgstrom A., Wakefield T.W., Whitehouse W.M., Stanley J.C. Protamine reversal of anticoagulation achieved with a low molecular weight heparin. The effects on eicosanoids, clotting and complement factors. Thromb Res 1987, 48:31-40.
31. Bull B.S., Huse W.M., Brauer F.S., Korpman R.A. Heparin therapy during extracorporeal circulation. II. The use of a dose-response curve to individualize heparin and protamine dosage. J Thorac Cardiovasc Surg 1975, 69:685-689.
32. Lim W., Dentali F., Eikelboom J.W., Crowther M.A. Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency. Ann Intern Med 2006, 144:673-684.
33. Van Ryn-McKenna J., Cai L., Ofosu F.A., Hirsh J., Buchanan M.R. Neutralization of enoxaparine-induced bleeding by protamine sulfate. Thromb Haemost 1990, 63:271-274.
34. Bang C.J., Berstad A., Talstad I. Incomplete reversal of enoxaparin-induced bleeding by protamine sulfate. Haemostasis 1991, 21:155-160.
35. Massonnet-Castel S., Pelissier E., Bara L., Terrier E., Abry B., Guibourt P., et al. Partial reversal of low molecular weight heparin (PK 10169) anti-Xa activity by protamine sulfate: in vitro and in vivo study during cardiac surgery with extracorporeal circulation. Haemostasis 1986, 16:139-146.
36. Firozvi K., Deveras R.A., Kessler C.M. Reversal of low-molecular-weight heparin-induced bleeding in patients with pre-existing hypercoagulable states with human recombinant activated factor VII concentrate. Am J Hematol 2006, 81:582-589.
37. Yank V., Stafford R.S. Safety of recombinant activated factor VII in randomized clinical trials. N Engl J Med 2012, 364:575.
38. Samama C.M., Godier A. Nouveaux anticoagulants : premier bilan. Sang Thrombose Vaisseaux 2009, 21:389-395.
39. Warkentin T.E., Maurer B.T., Aster R.H. Heparin-induced thrombocytopenia associated with fondaparinux. N Engl J Med 2007, 356:2653-2655. [discussion 5].
40. Rota E., Bazzan M., Fantino G. Fondaparinux-related thrombocytopenia in a previous low-molecular-weight heparin (LMWH)-induced heparin-induced thrombocytopenia (HIT). Thromb Haemost 2008, 99:779-781.
41. Schulman S., Kearon C., Kakkar A.K., Mismetti P., Schellong S., Eriksson H., et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009, 361:2342-2352.
42. Granger C.B., Alexander J.H., McMurray J.J., Lopes R.D., Hylek E.M., Hanna M., et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011, 365:981-992.
43. Mega J.L., Braunwald E., Wiviott S.D., Bassand J.P., Bhatt D.L., Bode C., et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012, 366:9-19.
44. Alexander J.H., Lopes R.D., James S., Kilaru R., He Y., Mohan P., et al. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med 2011, 365:699-708.
45. Oldgren J., Budaj A., Granger C.B., Khder Y., Roberts J., Siegbahn A., et al. Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. Eur Heart J 2011, 32:2781-2789.
46. Smogorzewska A., Brandt J.T., Chandler W.L., Cunningham M.T., Hayes T.E., Olson J.D., et al. Effect of fondaparinux on coagulation assays: results of College of American Pathologists proficiency testing. Arch Pathol Lab Med 2006, 130:1605-1611.
47. Desmurs-Clavel H., Huchon C., Chatard B., Negrier C., Dargaud Y. Reversal of the inhibitory effect of fondaparinux on thrombin generation by rFVIIa, aPCC and PCC. Thromb Res 2009, 123:796-798.
48. Gerotziafas G.T., Depasse F., Chakroun T., Samama M.M., Elalamy I. Recombinant factor VIIa partially reverses the inhibitory effect of fondaparinux on thrombin generation after tissue factor activation in platelet rich plasma and whole blood. Thromb Haemost 2004, 91:531-537.
49. Lisman T., Bijsterveld N.R., Adelmeijer J., Meijers J.C., Levi M., Nieuwenhuis H.K., et al. Recombinant factor VIIa reverses the in vitro and ex vivo anticoagulant and profibrinolytic effects of fondaparinux. J Thromb Haemost 2003, 1:2368-2373.
50. Young G., Yonekawa K.E., Nakagawa P.A., Blain R.C., Lovejoy A.E., Nugent D.J. Recombinant activated factor VII effectively reverses the anticoagulant effects of heparin, enoxaparin, fondaparinux, argatroban, and bivalirudin ex vivo as measured using thromboelastography. Blood Coagul Fibrinolysis 2007, 18:547-553.
51. Bijsterveld N.R., Vink R., van Aken B.E., Fennema H., Peters R.J., Meijers J.C., et al. Recombinant factor VIIa reverses the anticoagulant effect of the long-acting pentasaccharide idraparinux in healthy volunteers. Br J Haematol 2004, 124:653-658.
52. Bijsterveld N.R., Moons A.H., Boekholdt S.M., van Aken B.E., Fennema H., Peters R.J., et al. Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers. Circulation 2002, 106:2550-2554.
53. Mayer S.A., Brun N.C., Begtrup K., Broderick J., Davis S., Diringer M.N., et al. Recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med 2005, 352:777-785.
54. Buller H.R., Cohen A.T., Davidson B., Decousus H., Gallus A.S., Gent M., et al. Extended prophylaxis of venous thromboembolism with idraparinux. N Engl J Med 2007, 357:1105-1112.
55. Bousser M.G., Bouthier J., Buller H.R., Cohen A.T., Crijns H., Davidson B.L., et al. Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, non-inferiority trial. Lancet 2008, 371:315-321.
56. Savi P., Herault J.P., Duchaussoy P., Millet L., Schaeffer P., Petitou M., et al. Reversible biotinylated oligosaccharides: a new approach for a better management of anticoagulant therapy. J Thromb Haemost 2008, 6:1697-1706.
57. Buller H.R., Destors J.M., Gallus A.S. Idrabiotaparinux, a biotinylated Long-Acting Anticoagulant in the treatment of deep vein thrombosis (EQUINOX Study): safety, efficacy, and reversibility by avidin. Blood 2008, 112:18. [abstract 32].
58. Freyburger G., Macouillard G., Labrouche S., Sztark F. Coagulation parameters in patients receiving dabigatran etexilate or rivaroxaban: two observational studies in patients undergoing total hip or total knee replacement. Thromb Res 2011, 127:457-465.
59. Sié P., Samama C.M., Godier A., Rosencher N., Steib A., Llau J.V., et al. Chirurgies et actes invasifs chez les patients traités au long cours par un anticoagulant oral anti-IIa ou anti-Xa direct. Ann Fr Anesth Reanim 2011, 30:645-650.
60. Eerenberg E.S., Kamphuisen P.W., Sijpkens M.K., Meijers J.C., Buller H.R., Levi M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 2011, 124:1573-1579.
61. Marlu R., Hodaj E., Paris A., Albaladejo P., Crackowski J.L., Pernod G. Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers. Thromb Haemost 2012, 108:217-224.
62. Godier A., Miclot A., Le Bonniec B., Durand M., Fischer A.M., Emmerich J., et al. Evaluation of prothrombin complex concentrate and recombinant activated factor VII to reverse rivaroxaban in a rabbit model. Anesthesiology 2012, 116:94-102.
63. Weitz J.I., Hirsh J., Samama M.M. New anticoagulant drugs: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004, 126(3 Suppl.):265S-286S.
64. Warkentin T.E., Greinacher A., Koster A. Bivalirudin. Thromb Haemost 2008, 99:830-839.
65. Meddahi S., Samama M.M., Ansara A.J., Arif S., Warhurst R.D., Bove C.M., et al. Direct inhibitors of thrombin, hirudin, bivalirudin, and dabigatran etexilate. J Mal Vasc 2009, 36:24-32.
66. Ansara A.J., Arif S., Warhurst R.D. Weight-based argatroban dosing nomogram for treatment of heparin-induced thrombocytopenia. Ann Pharmacother 2009, 43:9-18.
67. Fisher K. Hemodialysis in heparin-induced thrombocytopenia 2001, Marcel Dekker Inc, New York, p. 409-27. 2nd ed.
68. Bove C.M., Casey B., Marder V.J. DDAVP reduces bleeding during continued hirudin administration in the rabbit. Thromb Haemost 1996, 75:471-475.
69. Diehl K.H., Romisch J., Hein B., Jessel A., Ronneberger H., Paques E.P. Investigation of activated prothrombin complex concentrate as potential hirudin antidote in animal models. Haemostasis 1995, 25:182-192.
70. Dickneite G., Nicolay U., Friesen H.J., Reers M. Development of an anti-bleeding agent for recombinant hirudin induced skin bleeding in the pig. Thromb Haemost 1998, 80:192-198.
71. Weitz J.I. Factor Xa or thrombin: is thrombin a better target?. J Thromb Haemost 2007, 5(Suppl. 1):65-67.
72. van Ryn J., Stangier J., Haertter S., Liesenfeld K.H., Wienen W., Feuring M., et al. Dabigatran etexilate-a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010, 103:1116-1127.
73. Samama M.M., Martinoli J.L., LeFlem L., Guinet C., Plu-Bureau G., Depasse F., et al. Assessment of laboratory assays to measure rivaroxaban-an oral, direct factor Xa inhibitor. Thromb Haemost 2010, 103:815-825.
74. Zhou W., Schwarting S., Illanes S., Liesz A., Middelhoff M., Zorn M., et al. Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran. Stroke 2011, 42:3594-3599.
75. van Ryn J., Ruehl D., Priepke H. Reversibility of the anticoagulant effect of high of the direct thrombin inhibitor dabigatran by recombinant factor VIIa or activated protrombin complex concentrate (abstract 0370). Haematologica 2008, 93(Suppl. 1):148.
76. Garber S.T., Sivakumar W., Schmidt R.H. Neurosurgical complications of direct thrombin inhibitors-catastrophic hemorrhage after mild traumatic brain injury in a patient receiving dabigatran. J Neurosurg 2012, 116:1093-1096.